On the tumour stage, KRAS mutation was reported highest in the late stage at 67.9% (95% CI: 59.3–75.5), while on location, the colon recorded the highest KRAS mutation of 61.2% (95% CI: 55.1–67.0). Here, KRAS is linked to neoplasm.